United States Parkinson's Disease Therapeutics Market Growth & Trends | Major Players 2025 - AbbVie Inc., Acadia Pharmaceuticals Inc., ZAMBON COMPANY S.P.A.

"Global Parkinson's Disease Therapeutics Market size reached US$ 5.92 Billion in 2024 and is expected to reach US$ 12.83 Billion by 2033, growing at a CAGR of 8.1% during the forecast period 2025-2033." As per DataM intelligence research report

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/parkinsons-disease-therapeutics-market?sp

United States: Recent Parkinson's Disease Therapeutics Developments

✅ In September 2025, Biogen launched a next-generation oral MAO-B inhibitor in Massachusetts.The therapy improves motor function and reduces "off" periods for Parkinson's patients.It targets moderate-to-advanced disease stages with enhanced tolerability.

✅ In August 2025, AbbVie invested $50 million to expand R&D and manufacturing facilities for Parkinson's therapeutics in Illinois.The expansion focuses on advanced gene therapy and biologics for disease modification.

✅ In July 2025, Acadia Pharmaceuticals introduced a novel dopamine agonist in California with improved efficacy and reduced side effects.The therapy supports both early and mid-stage Parkinson's patients and improves adherence through simplified dosing.

✅ In June 2025, Revance Therapeutics completed Phase 3 trials for a next-generation botulinum toxin therapy targeting Parkinson's-associated dystonia in New Jersey.The results demonstrated significant reduction in motor symptoms and improved patient quality of life.

Japan: Recent Parkinson's Disease Therapeutics Developments

✅ In September 2025, Takeda Pharmaceuticals launched a new oral MAO-B inhibitor for Parkinson's patients in Tokyo.The therapy enhances motor control and reduces off-time, aligning with Japan's growing focus on neurodegenerative disease management.

✅ In August 2025, Otsuka Pharmaceutical invested in R&D and local production facilities in Osaka for gene therapy and biologic-based Parkinson's treatments.The initiative supports innovative therapies for disease modification.Commercial availability is expected in 2026.

✅ In July 2025, Astellas Pharma introduced a novel dopamine agonist therapy in Kyoto targeting mid-stage Parkinson's patients.The therapy improves motor function and reduces adverse effects, supporting patient adherence.

✅ In June 2025, Kyowa Kirin completed clinical validation of a next-generation neuroprotective therapy for Parkinson's in Fukuoka.The therapy demonstrated improved motor and non-motor outcomes and will be deployed in major neurology centers nationwide.

Parkinson's disease Therapeutics Market: Drivers

The Parkinson's disease therapeutics market is experiencing significant growth as healthcare providers and patients increasingly seek effective treatments to manage the progressive neurological disorder characterized by motor dysfunction and non-motor symptoms. Rising adoption is driven by the growing prevalence of Parkinson's disease globally, coupled with increasing awareness of early diagnosis and disease management strategies. Additionally, the expansion of pharmacological options, including dopaminergic therapies, enzyme inhibitors, and novel neuroprotective agents, is fueling market demand. Investments in research and development, clinical trials, and patient support programs further support market growth. The emphasis on improving patient quality of life, symptom management, and long-term disease control is also contributing to rising adoption.

Technological advancements are significantly enhancing Parkinson's disease therapeutics. Innovations in novel drug formulations, extended-release delivery systems, and combination therapies improve efficacy, safety, and patient adherence. Development of advanced drug delivery methods, such as transdermal patches, infusion pumps, and oral dispersible tablets, enhances convenience and symptom control. Integration of precision medicine, biomarker identification, and AI-driven predictive analytics supports personalized treatment strategies and early intervention. Continuous research in gene therapies, stem cell therapies, and neuroprotective agents is expanding therapeutic options and improving clinical outcomes. With ongoing innovation and growing awareness of disease management, the Parkinson's disease therapeutics market is poised for substantial growth.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/parkinsons-disease-therapeutics-market?sp

Parkinson's disease Therapeutics Market: Major Players

AbbVie Inc., Acadia Pharmaceuticals Inc., ZAMBON COMPANY S.P.A., Eisai Co., Ltd., Merz Pharmaceuticals, LLC., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co., Ltd., Novartis AG, Boehringer Ingelheim International GmbH, Bausch Health Companies Inc., Amneal Pharmaceuticals LLC., F. Hoffmann-La Roche Ltd, UCB S.A., and Rusan Pharma, among others.

Segment Covered in the Parkinson's disease Therapeutics Market:

➥ By Disease Type: Familial Parkinson's Disease, Idiopathic Parkinson's Disease, Early-Onset Parkinson's Disease

➥ By Drug Class: Dopamine Agonists, Enzyme Inhibitors, Anticholinergics, Adenosine A2A Antagonists, Others

➥ By Route of Administration: Oral, Injectable, Transdermal

Research Process:

Both primary and secondary data sources have been used in the Parkinson's disease Therapeutics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Most Frequently Asked Questions in the Parkinson's disease Therapeutics Market Research Industry:

➠ Who leads the Parkinson's disease Therapeutics industry and what's their competitive positioning regarding capacity, performance, and profitability?
➠ What growth opportunities and market challenges do Parkinson's disease Therapeutics market vendors face?
➠ Which segments show the highest growth potential and market share distribution?
➠ What factors are driving or limiting Parkinson's disease Therapeutics market growth?
➠ What are the dominant sales and distribution strategies in the Parkinson's disease Therapeutics industry?

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=parkinsons-disease-therapeutics-market

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.